ATNF:NSD-180 Life Sciences Corp (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.27

Change

-0.59 (-15.28)%

Market Cap

USD 0.19B

Volume

1.79M

Avg Analyst Target

USD 11.00 (+236.39%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


180 Life Sciences Corp (ATNF) Stock Analysis:
Based on the 180 Life Sciences Corp stock forecasts from 1 analysts, the average analyst target price for 180 Life Sciences Corp is USD 11.00 over the next 12 months. 180 Life Sciences Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of 180 Life Sciences Corp is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, 180 Life Sciences Corp’s stock price was USD 3.27. 180 Life Sciences Corp’s stock price has changed by -2.14 % over the past week, -1.79 % over the past month and +27.24 % over the last year.

About

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibros ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+5.23 (+1.73%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

+10.57 (+3.17%)

USD87.92B 10.55 8.07
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.18%)

USD67.82B 10.14 7.73
VRTX Vertex Pharmaceuticals Incorpo..

-0.64 (-0.31%)

USD48.34B 24.52 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-31.73 (-9.17%)

USD33.38B N/A N/A
SGEN Seagen Inc

-7.93 (-5.00%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.30 (-0.80%)

USD25.21B 56.53 6.26
ALNY Alnylam Pharmaceuticals Inc

-11.49 (-6.28%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ATNF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.78% 84% B 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.78% 84% B 70% C-
Trailing 12 Months  
Capital Gain 27.24% 83% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.24% 83% B 72% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.93% 38% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.93% 37% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 13.62% 98% A+ 85% B
Risk Adjusted Return 21.50% 48% F 35% F
Market Capitalization 0.19B 41% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.23 28% F 25% F
Price / Cash Flow Ratio -50.16 91% A- 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -139.07% 19% F 15% F
Return on Invested Capital -14.78% 78% C+ 31% F
Return on Assets -22.33% 59% F 17% F
Debt to Equity Ratio 0.38% 79% C+ 89% B+
Technical Ratios  
Short Ratio 2.52 66% D 53% F
Short Percent 4.56% 47% F 35% F
Beta -0.23 96% A 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.